Suzanne Travers

8.3k total citations · 3 hit papers
14 papers, 6.0k citations indexed

About

Suzanne Travers is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Suzanne Travers has authored 14 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 8 papers in Epidemiology and 4 papers in Immunology. Recurrent topics in Suzanne Travers's work include Inflammatory Bowel Disease (9 papers), Microscopic Colitis (7 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Suzanne Travers is often cited by papers focused on Inflammatory Bowel Disease (9 papers), Microscopic Colitis (7 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Suzanne Travers collaborates with scholars based in United States, Canada and Israel. Suzanne Travers's co-authors include Paul Rutgeerts, Allan Olson, Brian G. Feagan, Bruce E. Sands, Daniel Rachmilewitz, Jewel Johanns, William J. Sandborn, Gary R. Lichtenstein, Jean‐Frédéric Colombel and Stephen B. Hanauer and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Journal of Allergy and Clinical Immunology.

In The Last Decade

Suzanne Travers

14 papers receiving 5.8k citations

Hit Papers

Infliximab for Induction and Maintenance Therapy for Ulce... 2004 2026 2011 2018 2005 2004 2006 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
    2005 2.9k citations Paul Rutgeerts, William J. Sandborn et al. New England Journal of Medicine profile →
  2. Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
    2004 1.6k citations Bruce E. Sands, Frank Anderson et al. New England Journal of Medicine profile →
  3. Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children
    2006 662 citations Jeffrey S. Hyams, Wallace Crandall et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suzanne Travers United States 9 5.0k 3.8k 1.6k 1.6k 458 14 6.0k
Tim Wyant United States 18 2.7k 0.5× 2.2k 0.6× 1.4k 0.8× 782 0.5× 262 0.6× 31 3.8k
J F Colombel United States 29 2.2k 0.4× 1.7k 0.4× 797 0.5× 1.4k 0.9× 421 0.9× 148 3.6k
Jewel Johanns United States 32 8.6k 1.7× 6.5k 1.7× 3.4k 2.1× 2.3k 1.5× 757 1.7× 119 10.4k
Maria Rosario United States 18 3.1k 0.6× 2.4k 0.6× 1.4k 0.8× 933 0.6× 183 0.4× 47 3.8k
Elena Ricart Spain 38 3.5k 0.7× 2.7k 0.7× 772 0.5× 2.0k 1.3× 183 0.4× 121 5.0k
Fabian Schnitzler Germany 24 2.4k 0.5× 1.8k 0.5× 906 0.6× 849 0.5× 212 0.5× 45 3.0k
Kimberly L. DeWoody United States 9 4.3k 0.9× 3.2k 0.8× 2.2k 1.3× 1.5k 1.0× 2.1k 4.6× 13 7.3k
Stephan Targan United States 16 2.1k 0.4× 1.5k 0.4× 710 0.4× 1.0k 0.7× 343 0.7× 45 3.1k
Bruce Salzberg United States 19 2.2k 0.4× 1.6k 0.4× 835 0.5× 681 0.4× 174 0.4× 39 2.8k
Xavier Hébuterne France 22 1.7k 0.3× 1.2k 0.3× 801 0.5× 795 0.5× 229 0.5× 73 2.9k

Countries citing papers authored by Suzanne Travers

Since Specialization
Citations

This map shows the geographic impact of Suzanne Travers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Travers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Travers more than expected).

Fields of papers citing papers by Suzanne Travers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Travers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Travers. The network helps show where Suzanne Travers may publish in the future.

Co-authorship network of co-authors of Suzanne Travers

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Travers. A scholar is included among the top collaborators of Suzanne Travers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Travers. Suzanne Travers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Travers, Suzanne. (2014). NYPL: Service Successes and Financial Struggles as Branches Meet Neighborhood Needs. Public Library Quarterly. 33(3). 236–255. 3 indexed citations
2.
Lichtenstein, Gary R., Allan Olson, Suzanne Travers, et al.. (2006). Factors Associated with the Development of Intestinal Strictures or Obstructions in Patients with Crohn's Disease. The American Journal of Gastroenterology. 101(5). 1030–1038. 155 indexed citations
3.
Hyams, Jeffrey S., Wallace Crandall, Subra Kugathasan, et al.. (2006). Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children. Gastroenterology. 132(3). 863–873. 662 indexed citations breakdown →
4.
Travers, Jeffrey B., et al.. (2006). Taste Reactivity and Fos Expression in GAD1-EGFP Transgenic Mice. Chemical Senses. 32(2). 129–137. 19 indexed citations
5.
Sandborn, William J., Brian G. Feagan, Jewel Johanns, et al.. (2005). A Randomized Placebo-Controlled Trial of Infliximab Therapy for Active Ulcerative Colitis. The American Journal of Gastroenterology. 100. S313–S313. 3 indexed citations
6.
Sandborn, William J., Jean‐Frédéric Colombel, Walter Reinisch, et al.. (2005). Infliximab Induces and Maintains Mucosal Healing in Ulcerative Colitis Patients. The American Journal of Gastroenterology. 100. S310–S310. 5 indexed citations
7.
Sandborn, WJ, Walter Reinisch, D Rachmilewitz, et al.. (2005). Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial. Zeitschrift für Gastroenterologie. 43(5). 39 indexed citations
8.
Rutgeerts, Paul, William J. Sandborn, Brian G. Feagan, et al.. (2005). Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 353(23). 2462–2476. 2925 indexed citations breakdown →
9.
Sands, Bruce E., Frank Anderson, Çharles N. Bernstein, et al.. (2004). Infliximab Maintenance Therapy for Fistulizing Crohn's Disease. New England Journal of Medicine. 350(9). 876–885. 1607 indexed citations breakdown →
10.
Hanauer, Stephen B., Carrie Wagner, Mohan Bala, et al.. (2004). Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clinical Gastroenterology and Hepatology. 2(7). 542–553. 498 indexed citations
11.
12.
Hassell, Alan E., Peter P. Lee, Honghui Zhou, et al.. (1999). Lack of Effect of Erythromycin and Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Steady‐State Intranasal Levocabastine. The Journal of Clinical Pharmacology. 39(1). 76–85. 8 indexed citations
13.
Corren, Jonathan, Gary S. Rachelefsky, Sheldon L. Spector, et al.. (1999). Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions. Journal of Allergy and Clinical Immunology. 103(4). 574–580. 16 indexed citations
14.
Hampel, Frank C., et al.. (1999). Efficacy and Safety of Levocabastine Nasal Spray for Seasonal Allergic Rhinitis. American Journal of Rhinology. 13(1). 55–62. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tim Wyant Breakdown of academic impact, for papers by J F Colombel Breakdown of academic impact, for papers by Jewel Johanns Breakdown of academic impact, for papers by Maria Rosario Breakdown of academic impact, for papers by Elena Ricart Breakdown of academic impact, for papers by Fabian Schnitzler Breakdown of academic impact, for papers by Kimberly L. DeWoody Breakdown of academic impact, for papers by Stephan Targan Breakdown of academic impact, for papers by Bruce Salzberg Breakdown of academic impact, for papers by Xavier Hébuterne
Rankless by CCL
2026